Braveheart Bio, Inc. Stock: price and insider trades · United States
2 insiders bought €47.5M of shares over the last 90 days, the latest by AH Bio Fund IV, L.P., filed 11 Aug 2026.
Who traded when
BuySale+3 other insiders
Since the insiders bought
- -19.5%Entry US$26.15 · Close 21 Oct 2026 US$21.04
- -19.5%Entry US$26.15 · Close 21 Oct 2026 US$21.04
- -23.6%Entry US$27.53 · Close 21 Oct 2026 US$21.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 9,132,420 sharesCommon StockSEC:0001231919-26-000859:0
- 9,132,420 sharesCommon StockSEC:0000947871-26-000782:0
- 9,132,420 sharesCommon StockSEC:0000947871-26-000783:0
- 1,666,667 shares@ US$18.001.60% mcap85.9% of flowCommon StockSEC:0000947871-26-000782:1Canonical exit: 5 Nov 2026 (T+90)
- 273,333 shares@ US$18.000.26% mcap14.1% of flowCommon StockSEC:0000947871-26-000782:2Canonical exit: 5 Nov 2026 (T+90)
- 273,333 shares@ US$18.000.26% mcap14.1% of flowCommon StockSEC:0000947871-26-000783:2Canonical exit: 5 Nov 2026 (T+90)
- 1,100,000 shares@ US$18.001.05% mcap100.0% of flowCommon StockSEC:0001231919-26-000859:1Canonical exit: 5 Nov 2026 (T+90)
- 1,666,667 shares@ US$18.001.60% mcap85.9% of flowCommon StockSEC:0000947871-26-000783:1Canonical exit: 5 Nov 2026 (T+90)
- 7,420,091 sharesCommon StockSEC:0001104659-26-093140:0
- 9,132,420 shares0Common StockSEC:0001193125-26-340528:0
- 7,990,867 shares0Common StockSEC:0001193125-26-340528:1
- 1,111 shares@ US$18.000.0011% mcap100.0% of flowCommon StockSEC:0001470831-26-000799:0Canonical exit: 5 Nov 2026 (T+90)
- 1,920,000 shares@ US$18.001.84% mcap53.3% of flowCommon StockSEC:0001193125-26-340528:2Canonical exit: 5 Nov 2026 (T+90)
- 1,680,000 shares@ US$18.001.61% mcap46.7% of flowCommon StockSEC:0001193125-26-340528:3Canonical exit: 5 Nov 2026 (T+90)
- 55,555 shares@ US$18.000.053% mcap100.0% of flowCommon StockSEC:0001470831-26-000796:0Canonical exit: 5 Nov 2026 (T+90)
- 83,333 shares@ US$18.000.080% mcap100.0% of flowCommon StockSEC:0001470831-26-000798:0Canonical exit: 5 Nov 2026 (T+90)
- 4,166 shares@ US$18.000.0040% mcap100.0% of flowCommon StockSEC:0001470831-26-000800:0Canonical exit: 5 Nov 2026 (T+90)
- 83,333 shares@ US$18.000.080% mcap100.0% of flowCommon StockSEC:0001470831-26-000801:0Canonical exit: 5 Nov 2026 (T+90)
- 27,777 shares@ US$18.000.027% mcap100.0% of flowCommon StockSEC:0001470831-26-000804:0Canonical exit: 5 Nov 2026 (T+90)
19 of 19 declarations
About Braveheart Bio, Inc.
The whole record at Braveheart Bio, Inc. fits in a few days: 17 filings published between August 7, 2026 and August 11, 2026, all for trades dated August 7, 2026. That day, 9 filers bought for EUR 107,694,545 in total, which is 11 open-market purchases with a median of EUR 1,301,545. No sale is recorded.
Three purchases dominate: two by Forbion Growth Opportunities Fund III Cooperatief U.A., a 10% owner, of EUR 29,987,713 and EUR 26,239,249, then one by Orbimed Advisors LLC (Director) of EUR 26,031,006. Forbion has 4 filings including 2 purchases, Orbimed 3 including 2 purchases, AH Bio Fund IV, L.P. (10% Owner) 2 including 1 purchase. Erez Chimovits (Director) and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (10% Owner) have one filing each. 6 other filings are not purchases.
Read moreShow less
The US health care company is valued at USD 1.83 billion, and 58.2% of the capital is held by insiders. 11 filers appear in the record, and filings are published the same day, as a median.
